Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7251953 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL41543 | 0.78 | CYP3A4 (0.39) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL844893 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL3615657 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL548251 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL4613513 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL2697748 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL71899 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL3286109 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL7895190 | 0.77 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181693-A1 | METHODS OF TREATING INFLAMMATORY SKIN DISORDERS | NEPSONE EHF (IS) | 2023-06-15 | — | — | US | disclosed |
| US-8518390-B2 | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120014921-A1 | TREATMENT OF STROKE AND OTHER ACUTE NEURAL DEGENERATIVE DISORDERS VIA INTRANASAL ADMINISTRATION OF UMBILICAL CORD-DERIVED CELLS | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014921-A1 | TREATMENT OF STROKE AND OTHER ACUTE NEURAL DEGENERATIVE DISORDERS VIA INTRANASAL ADMINISTRATION OF UMBILICAL CORD-DERIVED CELLS | NES, DCX, NGF | CYP3A4 4850/4885TDP1 1258/4885ALDH1A1 360/4885 |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | PPIG, PIN1, PPIH | CYP3A4 251/4885TDP1 2493/4885ALDH1A1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.